INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 57 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,543 | +31.7% | 7,328 | 0.0% | 0.00% | – |
| Q1 2023 | $1,172 | -75.1% | 7,328 | -13.7% | 0.00% | – |
| Q4 2022 | $4,714 | -99.9% | 8,494 | +10.2% | 0.00% | – |
| Q3 2022 | $9,169,000 | -16.1% | 7,705 | -55.4% | 0.00% | – |
| Q2 2022 | $10,934,000 | +22.0% | 17,292 | +120.0% | 0.00% | – |
| Q1 2022 | $8,962,000 | -92.2% | 7,861 | -84.5% | 0.00% | – |
| Q4 2021 | $114,250,000 | +109.5% | 50,778 | +218.4% | 0.00% | – |
| Q3 2021 | $54,539,000 | +441.1% | 15,947 | +373.1% | 0.00% | – |
| Q2 2021 | $10,079,000 | +503850.0% | 3,371 | +337000.0% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 1 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 1 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 1 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 1 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | -99.7% | 1 | -99.7% | 0.00% | – |
| Q3 2019 | $301,000 | -42.8% | 292 | 0.0% | 0.00% | – |
| Q2 2019 | $526,000 | -4.2% | 292 | 0.0% | 0.00% | – |
| Q1 2019 | $549,000 | +59.1% | 292 | 0.0% | 0.00% | – |
| Q4 2018 | $345,000 | -56.4% | 292 | 0.0% | 0.00% | – |
| Q3 2018 | $791,000 | +41.8% | 292 | 0.0% | 0.00% | – |
| Q2 2018 | $558,000 | -9.0% | 292 | 0.0% | 0.00% | – |
| Q1 2018 | $613,000 | +3.4% | 292 | 0.0% | 0.00% | – |
| Q4 2017 | $593,000 | -74.6% | 292 | -83.4% | 0.00% | – |
| Q3 2017 | $2,334,000 | -63.3% | 1,755 | -56.7% | 0.00% | – |
| Q2 2017 | $6,368,000 | +8869.0% | 4,056 | +18336.4% | 0.00% | – |
| Q1 2017 | $71,000 | +22.4% | 22 | -48.8% | 0.00% | – |
| Q4 2016 | $58,000 | -98.9% | 43 | -98.8% | 0.00% | – |
| Q3 2016 | $5,413,000 | +138.0% | 3,470 | +102.9% | 0.00% | – |
| Q2 2016 | $2,274,000 | -97.4% | 1,710 | -84.7% | 0.00% | – |
| Q4 2015 | $88,014,000 | +1.2% | 11,212 | +9.0% | 0.00% | – |
| Q3 2015 | $86,951,000 | +94.6% | 10,290 | +152.2% | 0.00% | – |
| Q2 2015 | $44,676,000 | +179.1% | 4,080 | +256.3% | 0.00% | – |
| Q1 2015 | $16,007,000 | -58.5% | 1,145 | -60.1% | 0.00% | – |
| Q3 2014 | $38,529,000 | +1090.6% | 2,871 | +1030.3% | 0.00% | – |
| Q2 2014 | $3,236,000 | +461.8% | 254 | +330.5% | 0.00% | – |
| Q1 2014 | $576,000 | -93.3% | 59 | -90.5% | 0.00% | – |
| Q4 2013 | $8,576,000 | -96.2% | 621 | -95.2% | 0.00% | – |
| Q3 2013 | $227,601,000 | -20.7% | 13,058 | -26.3% | 0.00% | – |
| Q2 2013 | $287,000,000 | – | 17,727 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |